Free Trial
NASDAQ:COCH

Envoy Medical 3/28/2025 Earnings Report

Envoy Medical logo
$0.83 -0.12 (-12.44%)
As of 02:13 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Envoy Medical EPS Results

Actual EPS
-$0.45
Consensus EPS
-$0.33
Beat/Miss
Missed by -$0.12
One Year Ago EPS
N/A

Envoy Medical Revenue Results

Actual Revenue
$0.04 million
Expected Revenue
$0.07 million
Beat/Miss
Missed by -$30.00 thousand
YoY Revenue Growth
N/A

Envoy Medical Announcement Details

Quarter
Time
Before Market Opens
Conference Call Date
N/A
Conference Call Time
N/A

Upcoming Earnings

Envoy Medical's next earnings date is estimated for Thursday, November 13, 2025, based on past reporting schedules.

Conference Call Resources

Envoy Medical Earnings Headlines

Envoy Medical (NASDAQ:COCH) vs. LENSAR (NASDAQ:LNSR) Critical Survey
Your Bank Account Is No Longer Safe
What If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what the Department of Justice just admitted in court—claiming cash isn't legally your property. What does that mean? It means Washington thinks they can seize, freeze, or drain your accounts—whenever they want.tc pixel
Envoy Medical Flat on Retiring Debt
See More Envoy Medical Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Envoy Medical? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Envoy Medical and other key companies, straight to your email.

About Envoy Medical

Envoy Medical (NASDAQ:COCH) (NASDAQ:COCH) is a medical device company focused on non-invasive neuromodulation therapies for dysphagia, a swallowing disorder that affects patients following neurological events or due to degenerative conditions. The company’s lead technology delivers targeted electrical stimulation designed to strengthen the muscles and neural pathways involved in the swallowing process.

Envoy Medical’s flagship therapy has received regulatory clearance from the U.S. Food and Drug Administration and is being introduced through rehabilitation centers, speech-language pathology clinics and acute care hospitals. The company works closely with healthcare providers to integrate its device into patient care pathways, supporting therapy both in clinical environments and at home.

Headquartered in the Minneapolis–Saint Paul metropolitan area, Envoy Medical currently serves the U.S. market and is evaluating opportunities for expansion into select international regions. Its leadership team combines expertise in medical device development, rehabilitation sciences and commercial operations, backed by private financing aimed at advancing innovative therapies for neurological and musculoskeletal disorders.

View Envoy Medical Profile

More Earnings Resources from MarketBeat